Board of Directors
Khalil Barrage is a Managing Director at Invus, based in New York. He joined Invus in 2003 and established its Public Equity activity. Since its inception, Invus Public Equity has concentrated its investments in the emerging innovative biotech companies. Prior to joining Invus, he worked at The Olayan Group in New York and ran their US equity portfolio for 15 years. He holds a BA in Economics from the American University of Beirut. He is a member of the board of Protagenic. As part of his philanthropic engagement, Khalil serves on the board of the Children of Armenia Fund and Solving Kids’ Cancer.
Gerry Brunk joined Lumira Capital and established its Boston office in 2002. Before Lumira, he was a life sciences entrepreneur and engagement manager in the health care practice of The Boston Consulting Group.
Dr. De La Rosa serves as the Chief Scientific Officer of the Drug Innovation Ventures at Emory (DRIVE) and the Emory Institute for Drug Development (IDD), focused on the discovery and development of antiviral drugs for the treatment of viral diseases of unmet medical need and global concern.
Prior to joining Emory University, Dr. De La Rosa was Senior Vice President of Business Development & Scientific Affairs with Pharmasset. From 2002 until its acquisition by Gilead Sciences (Nasdaq: GILD) for $11 billion in 2012, he was responsible for licensing, strategic transactions, and alliance management of collaborations and partnerships with pharmaceutical companies and universities. He provided business and scientific leadership to drug development programs for the treatment of HIV, Hepatitis B and Hepatitis C, including Sofosbuvir. Prior to Pharmasset, Dr. De La Rosa held both scientific and business positions at Visible Genetics, where he was responsible for the development and improvement of genotyping tests for HIV, Hepatitis B and Hepatitis C, including the first sequencing-based HIV drug resistance test to receive FDA approval. Dr. De La Rosa also held scientific positions at Innogenetics, Boston Biomedica, and Digene, developing molecular diagnostic tests for infectious diseases. He is an inventor and author on several U.S. patents and publications relating to molecular diagnostic methods, techniques and therapeutics for infectious diseases and cancer, and has served on Scientific Advisory Boards and Board of Directors of biotechnology companies.
Dr. De La Rosa earned a Fogarty Fellowship and an Intramural Research Training Award Fellowship from the National Institutes of Health, where he completed post-doctoral training in the Laboratory of Biochemistry and the Laboratory of Pathology of the National Cancer Institute. He holds a Bachelors Degree in Microbiology from the University of California, San Diego, and a Ph.D. in Microbiology from Miami University.
Greg Duncan is the President and Chief Executive Officer of Celtaxsys, Inc. He was most recently Executive Vice President and President of North American Operations for UCB. Prior to that, he was the President of European and Emerging Market Operations. Before UCB, Greg spent 17 years with Pfizer where he held several executive positions including Senior Vice President of Marketing and President of Pfizer’s Latin American Operations.
Rick is the COO & CFO of Alimera Sciences. He is responsible for strategic finance, accounting, distribution, logistics, human resources, and information technology. Rick brings a wealth of financial management experience to the team with both public and private ventures. Since joining Alimera, he led our financing activities, raising over $300 million in private and public equity, and debt financing.
Rick has been active in Atlanta’s business circle for more than 20 years, with experience that includes financial and accounting management, mergers and acquisitions, and initial public offerings, as well as entrepreneurial and start up operational activities. Rick is the founder of two consulting practices, Brand Ignition Group and Black River Holdings, Inc. He is also the former chief financial officer and senior executive vice president of Netzee, Inc., a provider of internet banking solutions to community banks that went public in 1999. Rick started his career in Arthur Andersen’s audit and business advisory practice where he was a senior manager and certified public accountant. Rick has previously served as the chairman of the board of directors and audit committee for Jones Soda Co., a Seattle-based publicly traded company, director and audit committee chairman of Color Imaging, Inc., an Atlanta-based publicly traded company, and vice chairman of the North Metro Miracle League, an Atlanta-based charitable organization. He has an accounting degree from Wake Forest University.
Maxim Gorbachev is a partner and portfolio manager at RusnanoMedInvest (RMI). Prior to RMI, he worked several positions for UCB Pharma in Moscow and Brussels including CFO for Russia and CIS.
Mr. Masters is the founder and managing member of Masters Capital Management, LLC, a U.S. equity based hedge fund. While Masters Capital is considered a generalist investor, the firm has historically had a significant focus in the transportation and energy sectors.
Mr. Masters is also known as an expert in capital and commodities markets regulatory matters. In that capacity he has testified in front of numerous congressional committees and government agencies, addressed consumer, corporate, and academic groups, and appeared in media outlets around the world. In 2010, he founded Better Markets, a nonprofit and nonpartisan organization which advocates on behalf of the public interest regarding market structure.
Additionally, Mr. Masters serves on the boards of several charitable and private organizations.
Nicole Vitullo joined Domain in 1999 and became a partner in 2004. Prior to Domain, she was senior vice president at Rothschild Asset Management, Inc.